Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 001-41696 ACELYRIN, INC. (Exact name of registrant as specified in its charter) | Delaware | 85-2406735 | | --- ...

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company’s special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company’s merger agreement with Alumis Inc. (Nasdaq: ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (Nasdaq: SLRN) at its Special Meeting of Stockholders. Martin Babler, P ...

ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction TodayACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that ACELYRIN stockholders vote “FOR” ...

Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reiterated its confidence that the proposed combination with Alumis Inc. (Nasdaq: ALMS) is the best path forward and the most value-maximizing outco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-K ________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to __________________ Commission file number ...

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan ("Rights Plan"). The ACELYRIN Board and management team continue t ...

Core Viewpoint - The merger between ACELYRIN, INC. and Alumis Inc. aims to create a leading clinical-stage biopharma company focused on immune-mediated diseases, enhancing long-term value for stockholders through a diversified late-stage portfolio and strong financial position [1][2]. Company Overview - Alumis is a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, with a focus on precision approaches to optimize clinical outcomes [7]. - ACELYRIN is dedicated to providing transformative medicines, with its lead program, lonigutamab, targeting thyroid eye disease [8]. Financial Position - As of December 31, 2024, Alumis had approximately $289 million and ACELYRIN had approximately $448 million in cash, cash equivalents, and marketable securities, leading to a pro forma cash position of approximately $737 million for the combined company [6]. - The combined company expects to have sufficient financial resources to support its pipeline and operational needs into 2027 [6]. Pipeline and Development - The merger will result in a diversified portfolio of late-stage clinical assets targeting large markets, including therapies for plaque psoriasis, systemic lupus erythematosus, thyroid eye disease, and multiple sclerosis [6]. - The combined company will benefit from multiple high-value catalysts and a strong management team with a successful track record in developing innovative therapies [2][6]. Transaction Details - The merger is expected to close in the second quarter of 2025, pending stockholder approvals and customary closing conditions [3]. - Alumis plans to file an S-4 registration statement and proxy statement related to the transaction following the completion of fiscal year 2024 audits [4].

Core Viewpoint - ACELYRIN, INC. has determined that the unsolicited interest from Concentra Biosciences is not expected to yield a superior proposal compared to the planned all-stock merger with Alumis Inc, which is believed to maximize long-term value for ACELYRIN stockholders [1][2] Company Overview - ACELYRIN, INC. is a late-stage clinical biopharma company focused on developing transformative medicines in immunology, with its lead program being lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye disease treatment [4] Transaction Details - The all-stock transaction with Alumis is expected to close in the second quarter of 2025, pending stockholder approvals and customary closing conditions [2] - ACELYRIN's Board of Directors continues to recommend that stockholders support the merger with Alumis [2] Advisory Information - Guggenheim Securities, LLC is serving as the financial advisor to ACELYRIN, while Fenwick & West LLP and Paul Hastings LLP are providing legal counsel [3]

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the r ...